MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

TLRY

6.88

+1.03%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

TLRY

6.88

+1.03%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

TLRY

6.88

+1.03%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

TLRY

6.88

+1.03%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

TLRY

6.88

+1.03%↑

Search

Neogen Corp

Slēgts

SektorsVeselības aprūpe

9.5 2.81

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.43

Max

9.65

Galvenie mērījumi

By Trading Economics

Ienākumi

-1.1M

-17M

Pārdošana

-13M

211M

EPS

0.09

Peļņas marža

-8.056

Darbinieki

2,974

EBITDA

2.2M

26M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+29.87% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-90M

2B

Iepriekšējā atvēršanas cena

6.69

Iepriekšējā slēgšanas cena

9.5

Ziņu noskaņojums

By Acuity

23%

77%

65 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Neogen Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 17. apr. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

2026. g. 17. apr. 18:15 UTC

Galvenie ziņu notikumi

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

2026. g. 17. apr. 16:49 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026. g. 17. apr. 16:49 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

2026. g. 17. apr. 22:58 UTC

Peļņas

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026. g. 17. apr. 21:32 UTC

Tirgus saruna

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Moody's Downgrades Belgium to A1 -- Market Talk

2026. g. 17. apr. 20:52 UTC

Peļņas

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026. g. 17. apr. 20:50 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 17. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 17. apr. 20:29 UTC

Peļņas

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

2026. g. 17. apr. 20:11 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Buy Neurona Therapeutics for Up to $1.15B

2026. g. 17. apr. 19:34 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2026. g. 17. apr. 19:34 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

2026. g. 17. apr. 19:31 UTC

Tirgus saruna
Galvenie ziņu notikumi

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

2026. g. 17. apr. 19:26 UTC

Tirgus saruna

U.S. Natural Gas Futures Edge Up -- Market Talk

2026. g. 17. apr. 19:21 UTC

Tirgus saruna

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

2026. g. 17. apr. 19:15 UTC

Tirgus saruna

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

2026. g. 17. apr. 19:07 UTC

Tirgus saruna

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

2026. g. 17. apr. 18:57 UTC

Galvenie ziņu notikumi

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

2026. g. 17. apr. 18:53 UTC

Iegādes, apvienošanās, pārņemšana

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

2026. g. 17. apr. 18:53 UTC

Iegādes, apvienošanās, pārņemšana

UCB 2026 Rev Guidance Unchanged

2026. g. 17. apr. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

2026. g. 17. apr. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

2026. g. 17. apr. 18:14 UTC

Tirgus saruna
Galvenie ziņu notikumi

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

2026. g. 17. apr. 18:00 UTC

Galvenie ziņu notikumi

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

2026. g. 17. apr. 18:00 UTC

Galvenie ziņu notikumi

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

2026. g. 17. apr. 17:31 UTC

Tirgus saruna
Galvenie ziņu notikumi

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

2026. g. 17. apr. 17:26 UTC

Tirgus saruna
Peļņas

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Salīdzinājums

Cenas izmaiņa

Neogen Corp Prognoze

Cenas mērķis

By TipRanks

29.87% augšup

Prognoze 12 mēnešiem

Vidējais 12 USD  29.87%

Augstākais 12 USD

Zemākais 12 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Neogen Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

1

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

5.17 / 5.99Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

65 / 348 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Neogen Corp

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared food products and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. The company was incorporated in 1981 and is headquartered in Lansing, Michigan.
help-icon Live chat